Skip to main content

Developments in Pharmaceutical and Biotech Patent Law 2015

 
Author(s): Daniel L. Reisner, David K. Barr
Practice Area: Intellectual Property
Published: Oct 2015
PLI Item #: 136819
CHB Spine #: G1240

David K. Barr concentrates in the areas of patent, trade secret, and unfair competition litigation and counseling. Mr. Barr's experience includes litigation in federal and state courts, appeals to the Federal Circuit Court of Appeals and practice before the US Patent and Trademark Office, including contentious inter partes proceedings. Mr. Barr has been lead trial counsel in many complex Hatch-Waxman and biotech patent infringement cases, and has counseled clients on product development and strategic patent planning. He has extensive experience in intellectual property transactions, including licenses and acquisitions. Mr. Barr has also conducted numerous patent due diligence investigations, and has drafted patent license and related agreements. His patent matters have involved a variety of technologies, including biotechnology, pharmaceuticals, industrial chemistry and biomedical and mechanical devices.

Mr. Barr has authored articles and has lectured on a variety of intellectual property issues. He is a co-author and co-editor of the treatise Pharmaceutical and Biotech Patent Law (Practising Law Institute, 2016).

Mr. Barr received his law degree from the George Washington University Law School, where he was an Associate Editor of the George Washington Journal of International Law and Economics.


Daniel Reisner focuses on patent and trade secret litigation, intellectual property licensing, and general complex commercial disputes. His intellectual property experience includes biotechnology, pharmaceuticals, ANDA litigations, medical devices, telecommunications, computers, plastic injection molding manufacture, and aerospace systems.

Mr. Reisner has worked on numerous trials and has broad experience in all phases of litigation. Examples of matters on which Mr. Reisner has worked include representation of Pfizer Inc. in a patent infringement suit brought by the University of Rochester involving Celebrex®, a multibillion-dollar drug for the treatment of arthritis. The case resulted in a victory for Pfizer with a decision by the Federal Circuit upholding the district court's decision invalidating the patent-in-suit on a motion for summary judgment. In a subsequent suit against a generic, Mr. Reisner represented Pfizer in obtaining a victory at trial and affirmance on appeal.

Mr. Reisner also represents clients in telecommunications- and computer-related patent disputes. The technologies involved aspects of broadband data and video transmission, coaxial cable and optical data transmission, headends, data centers, computer networking, satellite communication, NTSC, ATSC, MPEG and DOCSIS standards, videotex, handheld computing, memory, peripherals, and microprocessors.